Semaglutide for Fatty Liver (MASH): What the Approval Means
Roughly one American adult in three has fat in their liver that should not be there. Most will never know, because it produces no symptoms and rarely appears on a routine panel until it has been there for years. A minority will progress to inflammation, scarring and eventually cirrhosis — and until 2025, no widely used medication was approved to stop that progression.
On August 18 2025 the FDA approved semaglutide — as Wegovy — for adults with the inflammatory form of fatty liver disease and moderate-to-advanced scarring. It is the first GLP-1 with a liver indication, and it is one of the reasons the semaglutide-versus-tirzepatide conversation is not only about weight.
The names, briefly
The condition was renamed in 2023 and the old names are still everywhere. NAFLD — non-alcoholic fatty liver disease — is now MASLD: metabolic dysfunction-associated steatotic liver disease. The inflammatory, progressive form, once NASH, is now MASH: metabolic dysfunction-associated steatohepatitis. The change was made to stop defining the disease by what it is not, and to name what drives it — insulin resistance, excess weight, the same metabolic picture that drives type 2 diabetes and cardiovascular disease.
MASLD is fat in the liver. MASH is fat plus inflammation plus cell injury. Fibrosis is the scarring that follows, graded from F0 to F4, where F4 is cirrhosis. The approval covers MASH with F2 or F3 fibrosis — moderate to advanced — without cirrhosis.
What ESSENCE found
The ESSENCE trial enrolled 1,197 adults with biopsy-proven MASH and F2–F3 fibrosis, randomized two-to-one to weekly semaglutide or placebo. At 72 weeks, the two things that matter in liver disease were measured on repeat biopsy.
Resolution of steatohepatitis — the inflammation gone, the scarring no worse — occurred in 63% of the semaglutide group and 34% of placebo. Improvement in fibrosis — the scarring reduced by at least one grade, the inflammation no worse — occurred in 37% versus 22%.
Those are large effects for a disease that had no drug. The trial continues to 240 weeks to see whether the biopsy changes translate into fewer liver-related events — cirrhosis, transplant, liver cancer, death — which is the outcome that ultimately counts and has not yet been reported.
Who this applies to
The indication is specific and the diagnosis is not something a weight-loss assessment produces on its own. A person qualifies when they have MASH — not just fat — with F2 or F3 fibrosis, established by biopsy or, increasingly, by non-invasive tests that combine blood markers and imaging.
For the patient we usually see, the path looks like this. A baseline panel shows a raised ALT or GGT, or a fatty-liver pattern on a scan done for another reason, in someone carrying weight with a prediabetic glucose. That is MASLD until proven otherwise. The next step is staging: a FIB-4 score from the panel, then — where it is indeterminate or high — a FibroScan or an equivalent elastography test to estimate fibrosis. Only then does anyone know whether the liver indication applies, and only then is a hepatologist's involvement decided.
What we do not do is prescribe semaglutide "for the liver" on the strength of a raised ALT. The drug will likely help fatty liver at any stage through weight loss; the indication is for the stage where the evidence is, and staging is what separates a person who needs a hepatologist from one who does not.
Why tirzepatide gets no liver page
Tirzepatide has its own MASH trial — SYNERGY-NASH, a phase 2 study that found high rates of steatohepatitis resolution — and a phase 3 program in progress. It would be surprising if it did not work. It is not approved for MASH, and until it is, the liver indication is a semaglutide fact. For a patient whose liver is the main driver of the decision, that is a reason to choose semaglutide; for a patient whose sleep apnea is, the tirzepatide page points the other way.
What we measure, and keep measuring
Liver enzymes, FIB-4 components and the metabolic panel at baseline; enzymes and FIB-4 on a schedule; elastography where staging calls for it. Alcohol history taken seriously, because the "metabolic" in MASLD assumes alcohol is not the driver, and the semaglutide and alcohol page covers the overlap. And a hepatologist in the loop for anyone with F3 or above, because that is specialist territory whatever the medication.
Frequently asked questions
Wegovy was approved in August 2025 for adults with noncirrhotic MASH — the inflammatory form — with moderate-to-advanced fibrosis. It is not approved for simple fatty liver without inflammation, though weight loss helps that too.
At 72 weeks, steatohepatitis resolved in 63% on semaglutide versus 34% on placebo, and fibrosis improved in 37% versus 22%.
Staging — a FIB-4 score from blood tests, then elastography such as FibroScan where indicated, and sometimes biopsy. A raised ALT alone does not distinguish them.
It very likely helps through weight loss and has promising phase 2 data, but it is not approved for MASH.
The approval excludes cirrhosis. Cirrhosis is managed by a hepatologist, and any medication decision is theirs.
Often, with weight loss and treatment — but enzymes are a poor guide to fibrosis, which is what matters. Staging is repeated, not just the enzymes.
Where this fits in your plan
A baseline panel with liver enzymes and the components of a FIB-4 score is where this starts. The Semaglutide Injection page covers the medication; the liver indication is a reason to choose it, not a reason to skip the staging.
We measure first. Then we act.
References
- Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). NEJM 2025.
- Novo Nordisk. Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. August 18 2025.
- Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78:1966–1986.
- Rinella ME et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023;77:1797–1835 — FIB-4 and elastography staging pathway.
- Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). NEJM 2024;391:299–310.
- Back toSemaglutide Injection
- Semaglutide and alcoholPeople on semaglutide often drink less without trying. What the 2025 and 2026 trials found, why it happens, and the practical safety points if you do drink on it.Read
- Semaglutide and heart riskThe one weight-loss drug with a finished cardiovascular outcomes trial in people without diabetes. Who was in SELECT, what it found, and what it means if your ApoB is high.Read
- What a comprehensive metabolic panel coversThe CMP is the most-ordered blood test in medicine and the least explained. What its fourteen measurements cover, and the four things it deliberately does not.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.